Over the last two decades, knowledge on fecal biomarkers has substantially increased. Nowadays, these non-invasive markers of inflammation have significant clinical utility in the management of inflammatory bowel disease. Their use informs the decision to perform endoscopy before diagnosis is made right through to influencing therapeutic choices and the need for interval endoscopic assessment. In this review, the roles of two S100 proteins, calprotectin, and S100A12 are described along with that of lactoferrin, in the context of inflammatory bowel disease.
Introduction
Biomarkers of inflammation play an important role in inflammatory bowel disease (IBD). Their uses include determining the site and severity of inflammation, aiding therapeutic decision-making, and informing patient prognosis. While useful surrogates for the degree of inflammation are present, no current biomarker is completely reliable.
Over the last 20 years, there has been significant progress made in the identification, quantification, and validation of a range of fecal biomarkers of inflammation. These now play increasingly important roles in the diagnosis and assessment of IBD, both for Crohn's disease (CD) and ulcerative colitis (UC). While remaining an area of significant research, a number of these biomarkers have transitioned to become commercially available assays and point of care tests. Their utility in distinguishing functional from organic disease is now established as is their ability to predict those patients who are more likely to relapse and therefore potentially benefit from an escalation in medical therapy. Their use in elucidating the presence of remission (mucosal vs deep) continues to evolve. This review will focus on three most well-established fecal markers of inflammation: calprotectin, S100A12, and lactoferrin.
Rationale of considering fecal markers
Fecal biomarkers have considerable advantages over other types of biomarkers. In IBD, those measured in peripheral blood may be less sensitive than fecal biomarkers, which are in closer proximity to the site of inflammation. Radiological investigations can provide excellent anatomical detail pertaining to the intestine but are expensive and may expose the patient to significant doses of diagnostic medical radiation. 1 Gold standard tests such as ileocolonoscopy with mucosal biopsies are invasive, costly, and may not be well tolerated by patients, particularly if they need to be repeated with any degree of frequency.
Fecal biomarkers have a number of theoretical advantages over other biomarkers. Firstly, fecal samples are easy to collect and generally well accepted by patients. These features make it amenable to repeat sampling over a short period of time where necessary. Secondly, the fecal stream is in direct contact with the inflamed intestine, which should ensure that the concentration of specific biomarkers reflects the extent and severity of inflammation present. Thirdly, fecal biomarkers should be more specific for intestinal inflammation than serum tests, as the latter can be elevated by non-gastrointestinal causes for inflammation.
Criteria of an ideal fecal marker
The ideal fecal biomarker for intestinal inflammation would have a number of important characteristics. Firstly, it should be highly sensitive for inflammation anywhere along the gastrointestinal tract. Furthermore, the concentration of the fecal marker should reflect the extent and severity of inflammation. Robust cutoff concentrations should inform the presence of not only inflammation but also the response to therapy and ultimately mucosal healing. Ideally, the biomarker should be specific for intestinal inflammation without being elevated in non-intestinal causes of inflammation.
Secondly, the biomarker should be responsive to changes in inflammation-those caused by the institution or modification of therapy as well as those that signal disease relapse. Third, the biomarker should be temperature stable at room temperature for a number of days allowing for easy transportability as well as being able to be frozen without significantly affecting its concentration with thawing. This will allow batching of samples to be measured in a laboratory. The assay should be robust and has low intra-sample and inter-sample variability. Equally, a pointof-care option for quantitative measurement of the biomarker would be advantageous when therapeutic decisions need to be made more quickly.
The ideal fecal biomarker should also be routinely measured in IBD clinical trials as a biomarker of treatment efficacy and disease response. This provides a deeper understanding of drug efficacy and, potentially, duration of effect.
Historical fecal biomarkers
Over time, a number of techniques have been considered as potential ways to assess intestinal inflammation using stool samples. Unfortunately, these tools have various limitations.
The fecal excretion of radiolabeled white cells provides a sensitive assessment of gut inflammation. 2 However, as such studies are prolonged (taking up to 4 days) and require radiation exposure, they are not suited to routine clinical application.
The detection of white blood cells in the stool can also be a useful indicator of gut inflammation, in the absence of infection. However, the accuracy of this marker relies upon prompt examination of the stool sample to avoid degradation of white blood cells by gastrointestinal bacteria.
Methods for whole gut lavage were described late last century. Although this technique provided for the measurement of various markers (such as cytokines and neutrophil-derived proteins), it is not suitable for routine clinical use and remains a research tool.
The protease inhibitor α-1-antitrypsin is produced by epithelial cells and hepatocytes. While stable in stool, it is not acid stable. Levels of α-1-antitrypsin can be increased in stool consequent to disruption of the intestinal barrier, such as in protein-losing enteropathy. Prolonged collection and random samples can provide an estimate of gut inflammation; however, concerns of poor correlation to mucosal inflammation have been raised. 4 In addition, access to α-1-antitrypsin measurement is variable.
The S100 proteins: calprotectin and S100a12
The S100 protein family. The S100 family of proteins comprises at least 21 members, characterized as calcium-binding proteins with common distinct structures. 5 The proteins are small (approximately 10-12 kDa), can form homo or heterodimers or larger oligomers, and act as intracellular Ca 2+ signaling or Ca 2+ buffering proteins with many displaying high affinity for Zn 2+ and Cu 2+ ions. Several members of the S100 family also have extracellular activities.
The genes that code for S100 proteins are highly conserved, comprising 3 exons and 2 introns. Most of the S100 genes are clustered in the region of human chromosome 1q21. Three members of the S100 family, S100A8 (MRP8, calgranulin A), S100A9 (MRP14, calgranulin B), and S100A12 (calgranulin C), known as the calgranulin sub-family, are most relevant to inflammatory states.
5 S100A8 and S100A9 form the hetero-complex calprotectin-reflecting its calcium-binding and protective (antimicrobial) properties. Although S100A12 has a high degree of sequence homology with S100A8 and S100A9, 6 S100A12 only interacts with itself to form dimers and multimers. 7 S100A8, S100A9, S100A12, and calprotectin display a range of intracellular and extracellular activities. Intracellular roles include regulation of protein phosphorylation, 5 regulation of Nicotinamide adenine dinucleotide (NADH)-oxidation, 8 inhibition of kinase (but not cytidine monophosphate-kinase) activity, 9 intracellular Ca 2+ dependent translocation and regulation of intracellular Ca 2+ homeostasis, 10 binding arachidonic acids in neutrophils, 11 and protection from oxidative cell damage. 12 Extracellular activities include anti-microbial activity (in part through zinc chelation), 13 anti-fungal properties, inhibition of immunoglobulin production, 14 neutrophil and monocyte chemotaxis, 15, 16 induction of apoptosis, 17 and regulation of inflammation. 14 Calprotectin may also be involved in granuloma formation in CD, at least in part by recruiting mononuclear cells to the site of the lesion.
Calprotectin and S100A12 as disease markers. Both calprotectin and S100A12 are predominantly derived from, and constitutively expressed in, neutrophils. 18 Within neutrophils, calprotectin accounts for 60% of the total cytosolic protein, 18 while S100A12 constitutes 5% of cytosolic protein. 19 Other cell types, such as macrophages, epithelial cells, and eosinophils, may produce calprotectin. [20] [21] [22] S100A12 is also inducible in monocytes and T cells. 15 S100A8, S100A9, and S100A12 have been described as damageassociated molecular pattern molecules. Damage-associated molecular pattern molecules may be passively released by necrotic cells or actively secreted by activated monocytes or neutrophils and are considered to function as a communication mechanism between innate and adaptive immunity to regulate immune function. 23 It is due to these expression patterns that calprotectin and S100A12 are useful as disease markers. Calprotectin levels are elevated in a variety of gastrointestinal conditions (reviewed in Poullis et al.
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). Plasma calprotectin is elevated in alcohol-related liver disease, colorectal cancer, cystic fibrosis, and IBD. Calprotectin is also elevated in ascitic fluid in the setting of bacterial peritonitis and in cirrhosis. Tissue calprotectin is elevated in IBD, intestinal helminth infection, and colorectal cancer. Fecal calprotectin is elevated in non-steroidal anti-inflammatory drug enteropathy, pancreatic insufficiency, alcoholic enteropathy, colorectal cancer, and IBD. S100A12 is also elevated in a range of inflammatory conditions including cystic fibrosis (measured in bronchial fluid), 25 rheumatoid arthritis (serum), 26 and IBD (serum, mucosa, and feces). 27 While neither calprotectin nor S100A12 is disease-specific markers, their detection in disparate body fluids can be interpreted within context to provide disease-specific information. Elevated fecal levels of calprotectin and S100A12 are shown in active IBD, due to the numerous infiltrating neutrophils associated with the disease. 28 In contrast, neutrophils are relatively scarce in normal intestinal mucosa 29 with stool from a healthy individual having low levels of calprotectin 29 and virtually absent S100A12. 30 Consequently, both fecal calprotectin and S100A12 have been shown to provide a clear distinction between inflammatory disease, healthy controls, and functional bowel disorders. [31] [32] [33] Tibble et al. 32 used a single measure of fecal calprotectin to distinguish between adults with active CD and adults with no organic intestinal disorder with 100% sensitivity and 97% specificity. Similar distinctions have also been made for fecal S100A12, with Kaiser et al. 34 reporting a sensitivity of 86% and specificity of 96% for distinguishing adult IBD from Irritable Bowel Syndrome (IBS). Sidler et al. 33 reported 97% sensitivity and 100% specificity in distinguishing children with active IBD from children with no organic intestinal disease. There are fewer studies of fecal expression of S100A12 in diseases other than IBD. As the expression pattern of S100A12 is narrower, being essentially limited to neutrophils and monocytes, elevated levels of S100A12 would be expected to be more specific for acute inflammation. Nevertheless, the expression pattern of S100A12 in a broad range of diseases is still unmapped. It is also important to note that these markers have been assessed in infant, pediatric, and adult populations and to date there has been no difference between the genders in serum or fecal levels and in health or disease, for either marker.
Application of calprotectin and S100A12 as disease markers. The initial applications of calprotectin and S100A12 in the setting of IBD were as screening tools to guide the need for invasive investigations. As indicated previously, in patients with non-specific gastrointestinal symptoms, both calprotectin and S100A12 can distinguish IBD from functional bowel disorders with high sensitivity and specificity. However, there has been some debate about where the cutoffs between normal and elevated should be set. Husebye et al. 35 found considerable day-to-day variation in fecal calprotectin in patients without colonic inflammation and suggested a cutoff of 200 mg/kg is required to obtain greater test specificity. In addition, fecal calprotectin levels vary with age. Several reports indicate that newborn infants have high fecal calprotectin levels. 36, 37 One study reports that fecal calprotectin is higher in children between 2-9 years than in children older than 10 years. 38 In that study, the levels of fecal calprotectin were lower in infants whose mothers had received antibiotics before or at delivery, suggesting a link between fecal calprotectin excretion and the development of gut bacteria. Fecal calprotectin concentrations decline linearly over the first weeks of life, 36 remain high at 2 years of age compared with healthy adult levels, 37 and are generally comparable with adult levels by around the age of 5 years. 37 Nevertheless, Kostakis et al. 39 undertook a systematic review of the literature pertaining to fecal calprotectin use in the setting of childhood or adolescent IBD and concluded that 50 μg/g appears to be the most useful cutoff for this test.
A small number of reports have characterized the expression of fecal S100A12. However, recent work indicates that S100A12 has a different expression pattern to fecal calprotectin in infants. 40 Fecal S100A12 is generally equivalent to adult levels from birth. Transient increases of fecal S100A12 have been noted in infants <12 months of age, but at this time, it is not clear whether this is due to transient infection or normal physiology. A further consideration with fecal S100A12 is the lack of a standardized assay, unlike calprotectin, which may limit interpretation of results between different laboratories with independently developed assays. Therefore, at this stage, it would be premature to accept standardized cutoffs for fecal S100A12 until the assay becomes more widely available.
Markers of disease progression, location and prognosis. More recently, the application of fecal calprotectin and S100A12 has been investigated in the monitoring of remission and mucosal healing. Roseth et al. 41 reported that reduced fecal calprotectin concentrations are associated with mucosal healing.
Elevation of fecal calprotectin concentrations in an individual with IBD in remission could indicate enhanced risk of disease relapse. In adults, a single measure of fecal calprotectin provides a reasonable prediction of whether disease relapse will occur in the subsequent 12-month period, 42 although this predictive value is greater in UC than in CD. 43 Indeed, fecal calprotectin concentrations correlate with active histological inflammation even in cases of clinically and endoscopically quiescent UC. 44 Disease recurrence at the site of previous resection is commonplace in CD. 45 A recent systematic review 46, 47 confirmed the utility of fecal calprotectin as a predictor of recurrence in the subset of patients with CD who had undergone previous intestinal resection.
However, there is currently little data on the role of S100A12 in monitoring and prognosis of IBD. Boschetti et al. 48 recently suggested a role for fecal S100A12 as a measure of response to anti-tumor necrosis factor alpha therapy in patients with CD. The authors' suggested that a fall in concentrations of the S100A12 to <82 μg/g predicted a sustained clinical response, on maintenance treatment, 12 months following induction with an antitumor necrosis factor alpha agent. This lower concentration is in contrast to a cutoff of 139 μg/g suggested by Guidi et al. 49 for use with the same purpose.
In regard to assessing disease location, fecal S100A12 concentration appears to be an excellent indicator of disease activity in active colonic CD 31 yet provides only a modest indication of disease activity when disease is present at the terminal ileum or small intestine. 50, 51 Fecal calprotectin has been shown to correlate variably with capsule endoscopy disease scores 52 although it may be of some use in assessing small bowel disease.
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Additional features of calprotectin and S100A12. One study has also implicated fecal calprotectin as a potential predictor of predisposition to IBD in individuals at risk. Thjodleifsson et al. 53 reported elevated fecal calprotectin concentrations in 49% of first-degree relatives of IBD patients, indicating subclinical intestinal inflammation in these individuals. This increase was not evident in spouses of the patients with IBD. The authors suggest that this pattern may represent a single gene defect and that this gene is most likely associated with neutrophil activity. However, a limitation of the study was that only Icelandic IBD patients and their families were included.
In contrast, fecal calprotectin concentrations were not elevated in a group of siblings of children with known CD compared with age-matched healthy controls. 54 However, fecal S100A12 concentrations were greater in the siblings than in the control children (14 mg/kg vs 1 mg/kg: P < 0.001). Further study of the role of S100 proteins in the assessment of subclinical inflammation in individuals at risk of IBD is now required to fully elucidate the importance of these two findings.
Lactoferrin
Lactoferrin was first purified from mammalian milk in 1960. 55 It is a major whey protein, and early studies identified a close resemblance to transferrin, after which it was named. Lactoferrin is an iron-binding glycoprotein secreted from glandular epithelial cells and can be identified in secretions overlying most mucosal surfaces including saliva, tears, vaginal secretions, feces, synovial fluid, and mammalian breast milk. 56, 57 A lactoferrin receptor was identified on mucosal cells suggesting a role for this protein in the transfer of iron to the mucosa. 58 However, nearly all breast milk iron is bound to fat and low molecular-mass components, 59 suggesting that the role of lactoferrin in iron transportation may be limited. Nevertheless, lactoferrin also has antibacterial activity, whereby the iron binding activity of lactoferrin likely leads to iron sequestration depriving bacteria of this essential element.
Several reports have also shown lactoferrin to be a primary factor in acute inflammatory responses. 60 It is a major component of the secondary granules of neutrophils; its levels quickly increase during inflammation, 61 and lactoferrin concentrations are proportional to neutrophil flux. 62 In addition, lactoferrin is a stable molecule, resistant to proteolysis in the feces, 63 is unaffected by multiple freeze/thaw cycles, 54 and has been reported to remain stable in stool for 5 days. 64 Therefore, lactoferrin has key characteristics desirable for a disease marker.
With regard to the utility of lactoferrin in differentiating IBD from IBS, Sherwood 65 reviewed the published literature and identified that sensitivities for lactoferrin ranged from 78% to 88% and specificities from 85% to 100%. However, there are conflicting reports of whether lactoferrin may be of use in this setting. For example, Caccaro et al. 66 reported that lactoferrin was able to distinguish between organic and functional disease with a sensitivity of 88% and a specificity of 94%. Further, Sugi et al. 64 investigated lactoferrin, polymorphonuclear leukocytes (PMN)-elastase, lysozyme, and myeloperoxidase in feces and whole gut lavage fluid from patients with IBD and concluded that lactoferrin was a superior marker of intestinal inflammation. However, Silberer et al. 67 reported that of a number of biomarkers studied, only PMN-elastase and calprotectin and not lactoferrin were useful to differentiate chronic IBD from IBS. In a further study, Langhorst et al. 68 reported that lactoferrin and calprotectin differentiated active IBD from inactive IBD and IBS in 80% of cases, compared with 74% for PMN-elastase and 64% for C-reactive protein (CRP). The authors suggested that combining three markers (lactoferrin, calprotectin, and PMN-elastase) in a composite index may enhance test utility. However, other reports have indicated that combining lactoferrin and calprotectin concentrations did not provide additional benefits. 69, 70 In a further investigation, Judd et al. 71 compared fecal concentrations of calprotectin, lactoferrin, and S100A12 in children and found that calprotectin and lactoferrin correlated strongly with each other.
The potential utility of fecal lactoferrin in predicting those patients at risk of relapse has been investigated. Although only performed with a small sample size, the results indicate that elevation of fecal lactoferrin may occur prior to clinical flares.
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In addition, pediatric studies have shown fecal lactoferrin to be a sensitive and specific marker of inflammation in children with IBD: Fecal lactoferrin correlated with both clinical disease activity and serum inflammatory markers. 72 To date, there is no data on the patterns of lactoferrin according to disease location in IBD. Levels of lactoferrin appear to be similar in CD and UC, when active or inactive disease is present, as assessed in a small series from China. 73 A further possible limitation of lactoferrin is that fecal measurements are of limited benefit in breastfed infants because of the presence of lactoferrin in breast milk.
Overall, fecal lactoferrin is a good marker of inflammation and a sensitive indicator of neutrophil flux. Although fecal lactoferrin appears to provide similar information to fecal calprotectin, it has some limitations compared with calprotectin, suggesting its role in the setting of IBD may be restricted where fecal calprotectin is widely available.
Conclusions
A number of biomarkers have been evaluated over time as potential non-invasive indicators of inflammation in the gastrointestinal tract. Older markers (such as fecal white blood cell detection) have largely been superseded by more specific and sensitive biomarkers. Principal among these is fecal calprotectin although other neutrophil-derived proteins (lactoferrin and S100A12) have not yet been validated as extensively. Although the available biomarkers largely fulfill the criteria required of a fecal biomarker, none is yet able to fulfill all potential roles. Several markers provide high sensitivity and specificity for differentiating between IBD and functional gut symptoms: The use of biomarkers for this indication promises to ensure more prompt diagnosis and avoidance of unnecessary invasive investigations when screening tests are negative. Several of the current biomarkers provide clear indication of successful response to anti-inflammatory therapy. In contrast, further detailed evaluations are required to elucidate the best test to delineate mucosal healing and to predict the risk of future disease relapse.
